hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.

Tumor diameter was a significant prognostic factor for gemcitabine (HR 1.64: 95% CI 1.14–2.39 p = 0.010), but did not reach statistical significance as a prognostic factor for 5-FU treated patients (HR 1.31: 95% CI 0.89–1.96 p = 0.177) ( Table 1 ). 3.3.

also in 111,027 other papers

Notable differences in comparison to the previous reports are that performance status, tumor grade, local invasion, and smoking all failed to reach significance in the current publication, all of these can be explained by a reduction in power due to smaller numbers.

also in 4,113 other papers